Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.